4.1 Review

Diagnosis and treatment of postpartum bipolar depression

期刊

EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 10, 期 7, 页码 1045-1051

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.81

关键词

bipolar disorder; lactation; postpartum bipolar depression; postpartum hypomania; postpartum psychosis; screening; treatment

资金

  1. Astra-Zeneca
  2. Bristol-Myers Squibb
  3. Eli Lilly
  4. Janssen
  5. Lundbeck
  6. Ontario Mental Health Foundation
  7. Pfizer
  8. Servier
  9. Stanley Foundation

向作者/读者索取更多资源

The postpartum period is a time of increased risk of new-onset psychiatric illness, hospital admissions and out-patient psychiatric care for new mothers. Research into postpartum mood disorders has focused primarily on major depressive disorder, and has overlooked the study of bipolar disorder, particularly bipolar II disorder and bipolar disorder not otherwise specified. Failure to properly diagnose postpartum bipolar disorder may delay the initiation of appropriate treatment, lead to inappropriate treatment - thereby precipitating (hypo)mania, rapid cycling or a mixed episode - or result in polypharmacy and treatment refractoriness. The most serious consequence, however, is the high risk of infanticide and suicide among women with postpartum bipolar disorder. While no specific screening tools have been validated for postpartum mania or bipolar depression, symptoms of hypomania, atypical depression, a family history of bipolar disorder and a rapid onset of depressive symptoms following delivery may suggest a bipolar diathesis. In the absence of any pharmacological or psychotherapeutic treatments to guide clinical decision-making, it is recommended that the treatment of postpartum bipolar depression follow the same guidelines as the treatment of non-postpartum bipolar depression, using medications that are compatible with lactation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据